Treatment of asthma with Anti-tslp antibody

An antibody and asthma technology, applied in the field of anti-TSLP antibody treatment of asthma, can solve the problems of patients with asthma who cannot control moderate to severe asthma

Pending Publication Date: 2019-12-13
AMGEN INC +1
View PDF22 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The anti-TSLP antibodies described herein address an unmet need in patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of asthma with Anti-tslp antibody
  • Treatment of asthma with Anti-tslp antibody
  • Treatment of asthma with Anti-tslp antibody

Examples

Experimental program
Comparison scheme
Effect test

example

[0170] The anti-TSLP antibodies of the present invention are the first epithelial-targeted products that can have devastating efficacy in patients with non-eosinophilic and eosinophilic asthma. The high EOS group accounts for approximately 50%-70% of patients with severe asthma.

[0171] This example describes a multicentre, placebo-controlled, parallel-group, double-blind, phase 2 study conducted at 108 sites across 12 countries. Eligible patients were current never-smokers (≥6 months and with a history of 500 μg daily fluticasone or equivalent administered with the aid of a dry powder inhaler) combination therapy with inhaled corticosteroids for at least 6 months with poorly controlled asthma (according to defined severity GINA2012 Guidelines for Asthma 24). Patients were also required to have a history of at least two asthma exacerbations leading to systemic glucocorticoid therapy or one severe exacerbation leading to hospitalization within the 12 months prior to trial en...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Patent Application No. 62 / 484,864, filed April 12, 2017, U.S. Provisional Patent Application No. 62 / 553,477, filed September 1, 2017, and U.S. Provisional Patent Application No. 6, filed September 1, 2017 62 / 553,575, which are hereby incorporated by reference in their entirety. technical field [0003] The present disclosure relates generally to methods of treating asthma, including severe asthma, eosinophilic asthma, and non / hypoeosinophilic asthma, using antibodies specific for thymic stromal lymphopoietin (TSLP). Background technique [0004] Asthma is estimated to affect 315 million people worldwide. 1 Of these, approximately 10% to 15% have severe asthma 2 , and as many as 60% have uncontrolled disease. 3 These patients are at risk of severely impaired quality of life and recurrent severe exacerbations. Asthma therapy including inhaled corticosteroids (ICS) in combinati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/24C07K14/715A61K39/00
CPCC07K16/24C07K16/244C07K2317/21C07K2317/565A61P11/06A61K2039/505A61K2039/545A61K39/395A61K2039/55
Inventor J·R·帕尼斯J·格里菲思
Owner AMGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap